Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

被引：205
|
作者：
Alvarez-Fernandez, Monica [1 ,2 ]
Malumbres, Marcos [1 ]
机构：
[1] Spanish Natl Canc Res Ctr CNIO, Cell Div & Canc Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain
[2] Inst Invest Sanitaria Principado Asturias ISPA, Ave Roma S-N, Oviedo 33011, Spain
来源：
CANCER CELL | 2020年 / 37卷 / 04期
关键词：
CYCLIN-DEPENDENT KINASES; CELL LUNG-CANCER; BREAST-CANCER; TYROSINE PHOSPHORYLATION; THERAPEUTIC STRATEGY; INDEPENDENT FUNCTION; CDK6; INHIBITOR; OVARIAN-CANCER; PHASE-II; TUMOR;
D O I：
10.1016/j.ccell.2020.03.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.
引用
收藏
页码：514 / 529
页数：16
相关论文
共 50 条
  • [1] Resistance mechanisms to CDK4/6 Inhibition
    O'Leary, Ben
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 589 - 589
  • [2] CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
    Schaefer, Inga-Marie
    Hemming, Matthew L.
    Lundberg, Meijun Z.
    Serrata, Matthew P.
    Goldaracena, Isabel
    Liu, Ninning
    Yin, Peng
    Paulo, Joao A.
    Gygi, Steven P.
    George, Suzanne
    Morgan, Jeffrey A.
    Bertagnolli, Monica M.
    Sicinska, Ewa T.
    Marino-Enriquez, Adrian
    Hornick, Jason L.
    Raut, Chandrajit P.
    Demetri, George D.
    Ou, Wen-Bin
    Saka, Sinem K.
    Fletcher, Jonathan A.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [3] Novel mechanisms of acquired resistance to selective CDK4/6 inhibition
    Shapiro, Geoffrey I.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    [J]. CANCER RESEARCH, 2016, 76
  • [5] CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma
    Olanich, Mary E.
    Sun, Wenyue
    Hewitt, Stephen M.
    Abdullaev, Zied
    Pack, Svetlana D.
    Barr, Frederic G.
    [J]. CANCER RESEARCH, 2015, 75
  • [6] CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
    Olanich, Mary E.
    Sun, Wenyue
    Hewitt, Stephen M.
    Abdullaev, Zied
    Pack, Svetlana D.
    Barr, Frederic G.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4947 - 4959
  • [7] Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
    Scott, Susan Combs
    Lee, Sarah S.
    Abraham, Jame
    [J]. SEMINARS IN ONCOLOGY, 2017, 44 (06) : 385 - 394
  • [8] Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
    Paternot, Sabine
    Raspe, Eric
    Meiller, Clement
    Tarabichi, Maxime
    Assie, Jean-Baptiste
    Libert, Frederick
    Remmelink, Myriam
    Bisteau, Xavier
    Pauwels, Patrick
    Blum, Yuna
    Le Stang, Nolwenn
    Tabone-Eglinger, Severine
    Galateau-Salle, Francoise
    Blanquart, Christophe
    Van Meerbeeck, Jan P.
    Berghmans, Thierry
    Jean, Didier
    Roger, Pierre P.
    [J]. MOLECULAR ONCOLOGY, 2024, 18 (04) : 866 - 894
  • [9] The transcriptome of CDK4/6 inhibition
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    [J]. AGING-US, 2017, 9 (08): : 1859 - 1860
  • [10] Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA.
    Silva, Dilru
    Kinsey, Conan
    McMahon, Martin
    [J]. CANCER RESEARCH, 2021, 81 (22) : 22 - 23
12345